{"denoms":[{"counts":[{"groupId":"BG000","value":"114"},{"groupId":"BG001","value":"55"},{"groupId":"BG002","value":"107"},{"groupId":"BG003","value":"276"}],"units":"Participants"}],"groups":[{"description":"Study 1.\n\nEverolimus 10 mg orally daily for 4 week cycle. Repeat until progression, unacceptable toxicity, refusal, or alternative therapy at any time.\n\nEverolimus : Everolimus 10 mg orally daily for 4 week cycle. Repeat until progression, unacceptable toxicity, refusal, or alternative therapy at any time.","id":"BG000","title":"Relapsed Aggressive Non-Hodgkin Lymphoma"},{"description":"Study 2.\n\nEverolimus 10 mg orally daily for 4 week cycle. Repeat until progression, unacceptable toxicity, refusal, or alternative therapy at any time.\n\nEverolimus : Everolimus 10 mg orally daily for 4 week cycle. Repeat until progression, unacceptable toxicity, refusal, or alternative therapy at any time.","id":"BG001","title":"Relapsed Indolent Non-Hodgkin Lymphoma"},{"description":"Study 3. Includes Hodgkin's lymphomas.\n\nEverolimus 10 mg orally daily for 4 week cycle. Repeat until progression, unacceptable toxicity, refusal, or alternative therapy at any time.\n\nEverolimus : Everolimus 10 mg orally daily for 4 week cycle. Repeat until progression, unacceptable toxicity, refusal, or alternative therapy at any time.","id":"BG002","title":"Uncommon Lymphomas"},{"description":"Total of all reporting groups","id":"BG003","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"36","upperLimit":"92","value":"70"},{"groupId":"BG001","lowerLimit":"33","upperLimit":"85","value":"67"},{"groupId":"BG002","lowerLimit":"20","upperLimit":"85","value":"60"},{"groupId":"BG003","lowerLimit":"20","upperLimit":"92","value":"66"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"41"},{"groupId":"BG001","value":"25"},{"groupId":"BG002","value":"28"},{"groupId":"BG003","value":"94"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"73"},{"groupId":"BG001","value":"30"},{"groupId":"BG002","value":"79"},{"groupId":"BG003","value":"182"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"114"},{"groupId":"BG001","value":"55"},{"groupId":"BG002","value":"107"},{"groupId":"BG003","value":"276"}]}],"title":"United States"}],"paramType":"NUMBER","title":"Region of Enrollment","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"29"},{"groupId":"BG003","value":"29"}]}],"title":"Hodgkin Lymphoma"},{"categories":[{"measurements":[{"groupId":"BG000","value":"114"},{"groupId":"BG001","value":"55"},{"groupId":"BG002","value":"78"},{"groupId":"BG003","value":"247"}]}],"title":"Non-Hodgkin Lymphoma"}],"paramType":"NUMBER","title":"Hodgkin versus Non-Hodgkin Lymphoma","unitOfMeasure":"participants"}]}